Dynavax Technologies Corporation (OQ:DVAX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 2100 POWELL STREET, SUITE 900
Tel: N/A
Website: www.dynavax.com
IR: See website
Key People
Andrew A. F. Hack
Interim Independent Chairman of the Board
David F. Novack
President, Chief Operating Officer
Ryan Spencer
Chief Executive Officer, Director
Michael S. Ostrach
Chief Financial Officer, Senior Vice President, Chief Business Officer
Robert Janssen
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Justin Burgess
Principal Accounting Officer
Business Overview
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
Financial Overview
For the three months ended 31 March 2020, Dynavax Technologies Corporation revenues increased 89% to $10.9M. Net loss decreased 68% to $12.6M. Revenues reflect Product revenues, net increase of 87% to $10.5M, Other revenue increase from $146K to $405K. Lower net loss reflects Research and development - Balancing val decrease of 64% to $4M (expense), Compensation and related personnel costs decrease of 72% to $2.2M (expense).
Employees: 231 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,007M as of Mar 31, 2020
Annual revenue (TTM): $40.37M as of Mar 31, 2020
EBITDA (TTM): -$87.07M as of Mar 31, 2020
Net annual income (TTM): -$128.79M as of Mar 31, 2020
Free cash flow (TTM): -$136.09M as of Mar 31, 2020
Net Debt Last Fiscal Year: $50.05M as of Mar 31, 2020
Shares outstanding: 101,599,440 as of May 21, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization